Stanford researchers have developed a next-generation programmable transcriptional activation platform, TIGRa, that addresses key limitations of CRISPRa technologies, including large size, limited multiplexing capacity, and delivery constraints.
Researchers from Stanford have developed a novel topical pharmaceutical composition comprising of a chemical inhibitor encapsulated in nanomicelles for the treatment of vision loss associated with acute optic neuropathies.
Researchers at Stanford have developed a platform to design and screen novel chimeric large serine recombinases (LSRs), enzymes capable of inserting large DNA payloads into precise locations in the genome.
Stanford researchers have developed novel AsCas12a-expressing mouse models for simultaneous editing of multiple genomic loci in vivo with unique targeting capabilities relative to traditional Cas9 models, enabling the rapid creation of complex genotypes in somatic cells and ca
Stanford scientists have developed innovative methods for safely collecting, preserving, imaging, and molecularly profiling human brain tissue that remains on explanted intracranial electrodes used in neurosurgical procedures.
Stanford researchers have developed a novel gene therapy vector, AAV-capGL to overcome immune barriers that currently limit the efficacy and safety of adeno-associated virus (AAV)-based gene therapies.
Researchers at Stanford have developed a clinically applicable method of bone marrow conditioning for stem cell transplantation or treatment of hematologic malignancies.
Stanford researchers have developed a novel CRISPR-based method, Oligo-LiveFISH, for generating large-scale pools of synthetic RNA oligos that enable multiplexed targeting, imaging, and manipulation of genomic regions in living cells.
Stanford scientists have developed a new DNA-based technology that allows therapeutic genes to be maintained in human cells for extended periods without altering the cell's chromosomes.
Stanford researchers have developed a novel therapeutic approach for neurodegenerative diseases by targeting endoplasmic reticulum (ER) stress in neurons using CHOP inhibitors, with significant potential for development into first-in-class neuroprotective drugs for neurodegene
Stanford researchers have developed a non-viral, homology-independent method for precise targeted DNA insertions into T-cells using electroporation and CRISPR/Cas9, enabling cost-effective production of CAR T-cells for T-cell therapies.
Stanford scientists have developed a gene integration system that uses human-derived helicases paired with CRISPR technology to enable precise insertion of long DNA sequences at targeted genomic locations.
Stanford researchers have developed ModulADAR - a novel RNA sensing platform that enables precise, cell-type or state-specific activation of mRNA expression using ADAR editing, offering unparalleled flexibility and specificity for targeted RNA therapeutics.
Overweight and obesity are linked to an increased risk and worsened outcome from many cancers, including colorectal, pancreatic and breast cancer, but the mechanisms responsible for these phenomena are unknown.